GLP-1 skin reactions: what two cases show

Two case reports in Skin Health and Disease describe unusual skin reactions after starting GLP-1 receptor agonists: a sarcoidosis-like skin condition after semaglutide and a return of solar urticaria after liraglutide^[1]. They are signals worth knowing about, not proof that either medicine caused the reaction or an estimate of how often it occurs. The report contains two patients, and that is far too little evidence to define a population risk.

What the paper reports

The paper is a case report, not a trial or a database study. Its authors describe two women in their sixties who had skin events soon after beginning different GLP-1 medicines^[1]. The timing, clinical work-up and follow-up make the cases useful for clinicians and patients who encounter a similar pattern. They cannot separate a drug effect from coincidence, a predisposition, or an unrecognised trigger.

The first patient began semaglutide for weight control and developed tender nodules on her trunk and limbs four weeks later. A biopsy showed noncaseating granulomatous dermatitis. After infection testing and assessment for systemic disease, the clinical diagnosis was cutaneous sarcoidosis. The lesions were separate from injection sites. They resolved five months after semaglutide was stopped, without another intervention^[1]. The authors scored the suspected reaction as probable on the Naranjo adverse drug reaction scale.

The second patient had solar urticaria, a form of hives triggered by light, that had been in remission for more than 20 years. Five days after she started liraglutide for weight loss, it returned. Phototesting confirmed the diagnosis. Unlike the first case, the condition remained difficult to control after liraglutide was discontinued^[1]. The report again assigns a probable association, which is a structured way to judge a possible medication reaction rather than confirmation of causation.

Why the details matter

The report calls these the first published descriptions of cutaneous sarcoidosis and solar urticaria temporally associated with this drug class^[1]. That wording matters. A temporal association means the event followed treatment. It does not establish that treatment produced the event. In both cases, the authors looked for other explanations, but case reports cannot eliminate every alternative or tell readers how the pattern compares with people who never receive a GLP-1 medicine.

There is one reason the first report draws attention: the nodules appeared after the third injection, continued after the fourth, and resolved after the medicine was stopped. The authors also note that semaglutide has a reported sarcoidosis signal in the United Kingdom Yellow Card scheme^[1]. Spontaneous-reporting systems can identify possibilities, but they do not provide a denominator. A report in such a system cannot show that a medicine caused an event or calculate its frequency.

What this does and does not change

These two cases do not rewrite the established safety profile for GLP-1 receptor agonists. They add rare, unusual dermatology events to the list of questions that need larger studies. The paper itself notes that cutaneous adverse effects of GLP-1 receptor agonists had been reviewed in 2024 and that neither solar urticaria nor cutaneous sarcoidosis appeared in that earlier review^[1]. A future cohort or pharmacovigilance analysis could test whether either reaction is reported more often among treated patients than comparable untreated patients.

Mechanism is also unsettled. The authors discuss laboratory work on GLP-1 signaling, macrophages and immune regulation as possible routes for further research, but they do not present a mechanism proven in either patient^[1]. It would be a mistake to turn that discussion into a claim that semaglutide or liraglutide causes sarcoidosis, hives, or photosensitivity in general.

What to do with a new skin symptom

A new rash, firm nodules, swelling, or hives deserves clinical assessment on its own merits. The useful information to bring is practical: when the symptom began, where it appears, whether it follows light exposure, every medicine and supplement in use, and photographs taken as the change develops. A clinician can decide whether the pattern needs dermatology input, testing, or a different explanation.

Nothing in a two-patient report is a reason to start, stop, or adjust a prescribed medicine without speaking to the prescriber. The semaglutide safety overview covers the better-established adverse-event discussion on this site. If a skin reaction comes with trouble breathing, swelling of the face or throat, fainting, or rapidly spreading hives, seek urgent medical care.

What we do not yet know

We do not know the absolute risk of either reaction, whether a similar pattern occurs with other GLP-1 medicines, or which patient characteristics might increase susceptibility. We also do not know whether the solar urticaria recurrence was driven by liraglutide, the underlying disease course, or another factor. The semaglutide case improved after discontinuation, while the solar urticaria case did not quickly settle. Those different outcomes underline why two reports cannot support a simple class-wide rule^[1].

Medical disclaimer

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.